SEC Comment Letter 0000000000-25-003839 to LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc.
Date: April 10, 2025 · CIK: 0001815776 · Accession: 0000000000-25-003839
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286398
Letter
Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 Filed April 4, 2025 File No. 333-286398 Dear Evert Schimmelpennink:
April 10, 2025
Evert Schimmelpennink Chief Executive Officer LENZ Therapeutics, Inc. 201 Lomas Santa Fe Dr., Suite 300 Solana Beach, CA 92075
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ben Capps, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 10, 2025 Evert Schimmelpennink Chief Executive Officer LENZ Therapeutics, Inc. 201 Lomas Santa Fe Dr., Suite 300 Solana Beach, CA 92075 Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 Filed April 4, 2025 File No. 333-286398 Dear Evert Schimmelpennink: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ben Capps, Esq. </TEXT> </DOCUMENT>